WASHINGTON, DC – Scott Whitaker, president and CEO of the Advanced Medical Technology Association (AdvaMed), and Andy Fish, executive director of AdvaMedDx, today jointly issued the following statement on the Final Report of the Cancer Moonshot Task Force:
“The report issued today by Vice President Biden’s Cancer Moonshot Initiative is an encouraging step forward in achieving the important goal of eliminating cancer as we know it. We commend the Task Force and its working groups on this crucial effort.
“In particular, we applaud the Task Force for initiating several specific projects that will aid the development of new cancer technologies that will accelerate testing of therapies and characterization of tumors,” said Whitaker. “The medical technology industry contributes roughly $2 billion annually to the R&D that is producing products and technologies that support the diagnosis and treatment of people living with cancer. AdvaMed and AdvaMedDx member companies stand ready to support the recommendations by continuing to develop the much-needed technologies necessary to improve cancer treatment and care. We urge the Task Force increase its focus on diagnostics and radiotherapy in order to more accurately capture cancer care” Whitaker said.
Ad Statistics
Times Displayed: 22281
Times Visited: 445 Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money
Fish added, “The Task Force report once again underscores the critical role of diagnostic testing as a cornerstone of cancer care and the enabler of precision medicine. Many of the panel’s recommended activities will be driven by the use of diagnostics and contribute to the continued development of advanced diagnostic technologies and tests, including retrospective biospecimen analysis, networked data sharing, therapeutic target identification, and screening and early detection. We note that appropriate public policies – especially with regard to regulation and reimbursement, as well as access to biospecimens – are essential to ensuring robust progress in the research, development, commercialization and utilization of advanced diagnostic technologies.
“We hope to see that, as the Task Force works to carry out current initiatives and stand up its Year Two proposals that the remarkable developments and technological advances already available to diagnose and treat cancer are not forgotten as critical pieces of the cancer management puzzle. These include the radiotherapy technologies that are safer and more targeted than ever before and the diagnostic tests and imaging technologies that provide vital information that guide cancer diagnosis and treatment.”
Back to HCB News
